CIK 0001650664 · Non-accelerated filer<br>Smaller reporting company
Editas Medicine, Inc.
Sign in to watch- Ticker
- EDIT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464097528
- Phone
- 617-401-9000
- Business address
- 11 HURLEY ST., CAMBRIDGE, MA, 02141
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $19,092
- in 3 filings, $19K under 10b5-1 plans
Net −$19,092. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-30 | Hirsch Andrew Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-05-30 | Reeve Emma Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-05-30 | Levy Elliott M. Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-05-30 | Connaughton Bernadette Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-05-30 | Vaishnaw Akshay Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-05-20 | Lucera Erick EVP, CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −22,337 | $5.61 | $125K | 116,829 |
| 2024-05-13 | Hopfield Jessica Director | Purchase | +45,000 | $5.64 | $254K | 67,700 |
| 2024-03-05 | O'Neill Gilmore Neil CEO | Sale 10b5-1 | −77,824 | $9.42 | $733K | 327,470 |
| 2024-03-04 | Mei Baisong SVP, CHIEF MEDICAL OFFICER | Sale 10b5-1 | −20,327 | $9.42 | $191K | 141,543 |
| 2024-03-02 | Lucera Erick EVP, CHIEF FINANCIAL OFFICER | Grant or award | +35,300 | 113,200 | ||
| 2024-03-02 | Lucera Erick EVP, CHIEF FINANCIAL OFFICER | Grant or award | +25,966 | 139,166 | ||
| 2024-03-02 | Lucera Erick EVP, CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (right to buy) | +106,000 | 106,000 | ||
| 2024-03-02 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Grant or award | +24,800 | 69,967 | ||
| 2024-03-02 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Grant or award | +15,055 | 85,022 | ||
| 2024-03-02 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Grant or award · Stock Option (right to buy) | +74,400 | 74,400 | ||
| 2024-03-02 | O'Neill Gilmore Neil CEO | Grant or award 10b5-1 | +130,700 | 260,869 | ||
| 2024-03-02 | O'Neill Gilmore Neil CEO | Grant or award 10b5-1 | +72,213 | 333,082 | ||
| 2024-03-02 | O'Neill Gilmore Neil CEO | Grant or award 10b5-1 | +72,212 | 405,294 | ||
| 2024-03-02 | O'Neill Gilmore Neil CEO | Grant or award · Stock Option (right to buy) 10b5-1 | +392,100 | 392,100 | ||
| 2024-03-02 | Mei Baisong SVP, CHIEF MEDICAL OFFICER | Grant or award 10b5-1 | +50,900 | 122,955 |
Page 4 of 15 · 283 trades